Literature DB >> 12647301

Vascular smooth muscle cells efficiently activate a new proteinase cascade involving plasminogen and fibronectin.

Xavier Houard1, Catherine Monnot, Vincent Dive, Pierre Corvol, Maurice Pagano.   

Abstract

The plasminogen/plasmin system is involved in vascular wall remodeling after injury, through extracellular matrix (ECM) degradation and proteinase activation. Vascular smooth muscle cells (VSMCs) synthesize various components of the plasminogen/plasmin system. We investigated the conversion of plasminogen into plasmin in primary cultured rat VSMCs. VSMCs efficiently converted exogenous plasminogen into plasmin in a time- and dose-dependent manner. We measured plasmin activity by monitoring the hydrolysis of Tosyl-G-P-R-Mca, a fluorogenic substrate of plasmin. Cell-mediated plasmin activation was associated with the degradation of ECM, as revealed by fibronectin proteolysis. Plasmin also activated a proteinase able to hydrolyze Mca-P-L-G-L-Dpa-A-R-NH(2), a fluorogenic substrate of matrix metalloproteinases (MMPs). However, this proteinase was not inhibited by an MMP inhibitor. Furthermore, this proteinase displayed similar biochemical and pharmacological properties to fibronectin-proteinase, a recently identified zinc-dependent metalloproteinase located in the gelatin-binding domain of fibronectin. These results show that VSMCs convert exogenous plasminogen into plasmin in their pericellular environment. By hydrolyzing matrix protein plasmin activates a latent metalloproteinase that differs from MMP, fibronectin-proteinase. This metalloproteinase may participate to vascular wall remodeling, in concert with other proteinases. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12647301     DOI: 10.1002/jcb.10460

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  Common and specific effects of TIE2 mutations causing venous malformations.

Authors:  Marjut Nätynki; Jaakko Kangas; Ilkka Miinalainen; Raija Sormunen; Riikka Pietilä; Julie Soblet; Laurence M Boon; Miikka Vikkula; Nisha Limaye; Lauri Eklund
Journal:  Hum Mol Genet       Date:  2015-08-28       Impact factor: 6.150

2.  Plasminogen activator inhibitor-1 impairs plasminogen activation-mediated vascular smooth muscle cell apoptosis.

Authors:  Patrick Rossignol; Eduardo Anglès-Cano; Henri Roger Lijnen
Journal:  Thromb Haemost       Date:  2006-11       Impact factor: 5.249

Review 3.  Plasminogen receptors: the first quarter century.

Authors:  Lindsey A Miles; Robert J Parmer
Journal:  Semin Thromb Hemost       Date:  2013-03-26       Impact factor: 4.180

4.  Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis.

Authors:  Jeffrey C Horowitz; David S Rogers; Richard H Simon; Thomas H Sisson; Victor J Thannickal
Journal:  Am J Respir Cell Mol Biol       Date:  2007-07-26       Impact factor: 6.914

5.  Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques.

Authors:  P Rossignol; A Luttun; J L Martin-Ventura; F Lupu; P Carmeliet; D Collen; E Anglès-Cano; H R Lijnen
Journal:  J Thromb Haemost       Date:  2006-03       Impact factor: 5.824

6.  Plasminogen inhibits TNFalpha-induced apoptosis in monocytes.

Authors:  Jennifer W Mitchell; Nagyung Baik; Francis J Castellino; Lindsey A Miles
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

7.  Neutrophil apoptosis: selective regulation by different ligands of integrin alphaMbeta2.

Authors:  Elzbieta Pluskota; Dmitry A Soloviev; Dorota Szpak; Christian Weber; Edward F Plow
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

8.  Protective role of frizzled-related protein B on matrix metalloproteinase induction in mouse chondrocytes.

Authors:  Carole Bougault; Sabrina Priam; Xavier Houard; Audrey Pigenet; Laure Sudre; Rik J Lories; Claire Jacques; Francis Berenbaum
Journal:  Arthritis Res Ther       Date:  2014-07-01       Impact factor: 5.156

Review 9.  Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer.

Authors:  Lianghua Fang; Qing Xu; Jun Qian; Jin-Yong Zhou
Journal:  Onco Targets Ther       Date:  2021-01-06       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.